Abstract: A description is given of formulations comprising solid and stable creatine/citric acid composition(s) and carbohydrate(s) or hydrates thereof having a weight ratio of the constituents creatine/citric acid composition(s) and carbohydrate(s) of 1:0.01 to 1.0. Carbohydrate components, which can be used in anhydrous form, as hydrates or as moist products, are in principle all polyhydroxyaldehydes and polyhydroxyketones. The creatine component is preferably used in anhydrous form or in aqueous alcoholic or organic solution. The formulations should preferably be prepared by reacting the carbohydrates in the form of solutions, suspensions or as solid substance with the creatine/citric acid composition or solution thereof at ?20 to 120° C. and, if appropriate, finally removing the liquid phase, or else by a thermal treatment, a treatment with ultrasound or microwave of mixtures consisting of the creatine component and solid carbohydrates, preferably in a vacuum.

Abstract: The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed.

Abstract: The invention concerns a formulation containing phosphatidylserine (PS) and/or lyso-phosphatidylserine for preventing and treating mental and physical stress states, where the phosphatidylserine is, among others, combined with plant extracts or essences. Daily doses of 50 to 1000 mg PS are envisaged within the scope of the present invention which are administered over a maximum period of six months. Preferred subjects are humans of 10 to 50 years of age.

Abstract: The invention relates to addition and/or co-ordination compounds consisting of creatine and citric acid in the ratio of >1.0 to 3.0:1.0. Said compounds are characterised in that they have (KBr) bands in the IR spectrum, where &ngr;=3425 (±5) cm−1 (s), 1624 (±5) cm−1 (m-s) and 1247 (±5) cm−1 (m). Said compounds, which preferably contain no organic solvent and are present in a solid, pulverulent form are produced in particular by a method, according to which, a1) creatine, containing a maximum content of 20 wt. % water, is reacted with citric acid or its salts at temperatures between 0 and 70° C., or a2) creatine and citric acid or its salts, containing a total water content of between 5 and 15 wt. %, are ground at temperatures between 0 and 70° C., or a3) creatine is reacted with citric acid or its salts, in the presence of a solvent at temperatures between 0 and 70° C. The corresponding solvent is then eliminated to a maximum residual content of 1.

Abstract: The invention relates to choline pyruvate of formula (I) wherein 0<n≦10, and is a stabile, physiologically compatible formulation containing said choline pyruvate, water and/or an organic solvent such as glycerine, or is present in a solid and preferably a powder form. The invention also relates to a method for producing choline pyruvate, whereby choline hydroxide is placed in a solvent, such as water or a methanol/water mixture, at a temperature of between 0 and 98° C., then pyruvric acid is added drop by drop in external cooling conditions and mixed until a pH value of between 5.0 and 8.0 is reached, the solvent is then removed and finally the obtained product is added to a physiologically compatible solvent.

Abstract: A new composition for effecting serum cholesterol levels is claimed, said composition comprising a) at least a waxy acid with 23 to 50 carbon atoms or derivatives thereof and with serum cholesterol level reducing properties, and b) 0 to 99.99% by weight of at least a component with serum cholesterol level effecting properties, and c) 0 to 20% by weight of at least a pharmaceutically acceptable formulation aid. The efficacy of this composition can be enhanced by further incorporation of other cholesterol reducing agents, like lecithin, tocotrienol, saponins, fibers, long-chain waxy alcohols and niacin. The claimed composition combines the benefits of the single physiolocology active constituence together with the technology to increase the biovailability.

Abstract: The invention relates to the use of creatine and/or creatine derivatives for treating typical disorders in women, for example PMS or dysmenorrhea, which involves the prophylactic of therapeutic use, in particular, of creatine monohydrate, creatine pyruvates, creatine ascorbates and creatine &agr;-ketoglutarates as creatine derivatives in preferred daily doses of 0.1 g to 20 g. The invention also provides for the use of creatine or its derivatives as mixtures with a pyruvate, ascorbate or &agr;-ketoglutarate. The creatine or its appropriate derivatives are not restricted to any particular form of application, which makes them all the more suitable for the many symptoms of typical female disorders.

Abstract: The invention relates to the use of creatine and/or creatine derivatives for treating typical disorders in women, for example PMS or dysmenorrhea, which involves the prophylactic of therapeutic use, in particular, of creatine monohydrate, creatine pyruvates, creatine ascorbates and creatine &agr;-ketoglutarates as creatine derivatives in preferred daily doses of 0.1 g to 20 g. The invention also provides for the use of creatine or its derivatives as mixtures with a pyruvate, ascorbate or &agr;-ketoglutarate. The creatine or its appropriate derivatives are not restricted to any particular form of application, which makes them all the more suitable for the many symptoms of typical female disorders.